Case selection for interferon treatment of hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 15, Issue SUPPL. MAY, 2000, Pages

  Zeniya, Mikio ^a   Toda, Gotaro ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; INTERFERON; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; RIBAVIRIN; VIRUS RNA;

ADULT; AGE; AGED; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT SELECTION; PRIORITY JOURNAL; SEROTYPE; SEX DIFFERENCE; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS GENOME; VIRUS LOAD; VIRUS MUTATION;

EID: 0033948584     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2000.02111.x     Document Type: Conference Paper

References (30)

1. Shiratori Y, Kato N, Yokosuka O et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 1997; 113: 558-66.
2. Yoshioka K, Yano M, Kusakabe A et al. Randomized controlled trial of lymphoblastoid interferon-7α for chronic hepatitis C (comparison of 9-MU and 6-MU doses). Am. J. Gastroenterol. 1999; 94: 164-8.
3. Knolle PA, Kremp S, Höhler T, Krummenauer F, Schirmacher P, Gerken G. Viral and host factors in the prediction of response to interferon-7α therapy in chronic hepatitis C after long-term follow-up. J. Viral Hepatitis 1998; 5: 399-406.
4. Martinot-Peignoux M, Boyer N, Pouteau M et al. Predictors of sustained response to interferon-7α therapy in chronic hepatitis C. J. Hepatol. 1998; 29: 214-23.
5. Chayama K, Tsubota A, Kobayashi M et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 1997; 25: 745-9.
6. Di Marco V, Lo Iacono O, Gammà C et al. A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C. J. Med. Virol. 1997; 51: 17-24.
7. Chemello L, Cavalletto Noventa L, Bonetti F, Casarin C, Bernardinello E et al. Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-α. J. Viral Hepatitis 1995; 2: 91-6.
8. Kobayashi M, Chayama K, Arase Y et al. Predictive value of different hepatitis C serological assays in the treatment of chronic hepatitis C with interferon-α. J. Gastroenterol. 1999; 34: 94-9 .
9. 2a therapy in patients with chronic hepatitis C. Dig. Dis. Sci. 1994; 39: 1237-80.
10. Kasahara A, Hayashi N, Mochizuki K et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998; 27: 1394-402.
11. Karino Y, Toyota J, Yamazaki K et al. Analysis of the factors regulating the clinical effect of interferon therapy for chronic hepatitis C patients with more than 1 mEq/ml of HCV RNA. Acta Hepatol. Jpn. 1999; 40: 74-8.
12. Arase Y, Chayama K, Tsubota A et al. Interferon therapy for HCV-RNA positive chronic hepatitis. Acta Hepatol. Jpn. 1993; 33: 1-7.
13. Shindo M, Arai K, Sokawa Y, Okuno T. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-α therapy. Ann. Intern. Med. 1995; 122: 586-91.
14. De Salvo GL, Noventa F, Chemello L et al. Variables that influence response to different interferon schedules in chronic hepatitis C and predictive models. J. Viral Hepatitis 1997; 4: 79-83.
15. Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26 (Suppl.): S122-7.
16. Yuki N, Hayashi N, Kasahara A et al. Pre-treatment viral load and response to prolonged interferon-α course for chronic hepatitis C. J. Hepatol. 1995; 22: 457-63.
17. Garson JA, Brillanti S, Whitby K et al. Analysis of clinical and virological factors associated with response to interferon-α therapy in chronic hepatitis C. J. Med. Virol. 1995; 45: 348-53.
18. Booth JC, Foster GR, Kumar U et al. Chronic hepatitis C virus infection: Predictive value of genotype and level of viremia on disease progression and response to interferon-α. Gut 1995; 36: 427-32.
19. Camps J, Garcia-Granero M, Riezo-Boj JI et al. Prediction of sustained remission of chronic hepatitis C after a 12-month course of interferon-α. J. Hepatol. 1994; 21: 4-11.
20. Indilman R, de Maria N, Colantoni A, Dokmeci A, Van Thiel DH. Interferon treatment of cirrhotic patients with chronic hepatitis C. J. Viral Hepatitis 1997; 4: 81-91.
21. Schalm SW, Fattovich G, Brouwer J. Therapy of hepatitis C in patients with cirrhosis. Hepatology 1997; 26 (Suppl. 1): S128-32.
22. Manabe N et al. Hepatology 1993; 18: 1344-9.
23. Poynard. Lancet 1997; 349: 825-32.
24. Yano M, Kumada H, Kage M et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334-40.
25. Sangiovanni A, Morales R, Spinzi G et al. Hepatology 1998; 27: 853-6.
26. Van Thiel et al. Eur. J. Gastroenterol. Hepatol. 1995; 7: 165-8.
27. Benvegnu L, Fattovich G, Noventa F et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1998.
28. Martnot-Peignoux A. J. Hepatol. 1998.
29. Fukuda R, Ishimura N, Kushiyama Y et al. Effectiveness of interferon-α therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver. J. Hepatol. 1997; 26: 435-61.
30. Ohkawa Y, Takahashi H, Zeniya M, Aizawa Y, Sakaguchi M, Toda G. Changes of serum level of IL-1 receptor antagonist (IL-1ra) in the patients with type C chronic hepatitis during interferon therapy. Int. Hepatol. Commun. 1996; 5: 274-81.